Investor Centre

Pharmaxis Ltd's (ASX:PXS) (FRA:UUD) CEO Gary Phillips tells Proactive's Andrew Scott its drug PXS-5505 will be the focus of a new study, funded by a grant from the Charlie Teo Foundation, looking at an aggressive and deadly form of brain cancer. The drug, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Watch the interview here.